Nordic 5-Fluorouracil/Leucovorin Bolus Schedule Combined with Oxaliplatin (Nordic FLOX) as First-line Treatment of Metastatic Colorectal Cancer

Acta Oncologica

Volumn 42, Issue 8, 2003, Pages 827-831

  Sørbye, Halfdan ^a   Dahl, Olav ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BOLUS INJECTION; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; HEMOLYSIS; HUMAN; MALE; METASTASIS; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 0346495977     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310018972     Document Type: Article

References (22)

1. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001; 40: 282-308.
2. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
3. Glimelius B, Jakobsen A, Graf W, et al. Bolus injection (2-4 min) versus short term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Eur J Cancer 1998; 34: 674-8.
4. Jakobsen A, Berglund A, Glimelius B, et al. Dose-effect relationship of bolus 5-FU in the treatment of advanced colorectal cancer. Acta Oncol 2002; 41: 525-31.
5. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil- leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
6. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
7. Levi F, Zidani R, Misset JL, et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6.
8. Glimelius B, Ristamaki R, Kjaer M, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-73.
9. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization; 1979.
10. Sørbye H, Bruserud Ø, Dahl O. Oxaliplatin-induced haemato-logical emergency with an immediate severe thrombocytopenia and haemolysis. Acta Oncol 2001; 40: 882-3.
11. Seitz JF, Bennouna J, Paillot B, et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002; 13: 1072-9.
12. Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002; 20: 1759-66.
13. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307-12.
14. Comba AZ, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 2001; 37: 1006-13.
15. Morton RF, Goldberg RM, Sargent DJ, et al. Oxaliplatin or CPT-11 combined with 5FU/leucovorin in advanced colorectal cancer: an NCCTG/CALGB study. J Clin Oncol 2001; 20: Proc ASCO abstr 495.
16. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol 2002; 20: 2545-50.
17. Hochster HS, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003; 21: 2703-7.
18. Graf W, Pahlman L, Bergstrom R, Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-63.
19. Louvet C, de Gramont A, Tournigand C, et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91: 2033-8.
20. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-64.
21. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-70.
22. Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin in combination with capecitabine in patients with advanced colorectal cancer. J Clin Oncol 2003; 21: Proc ASCO abstr 1445.